Related Experiment Video
Updated: Jan 18, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies
Andriy Krendyukov1, Christian Gieffers1
1Apogenix AG, Heidelberg, Germany.
Abstract:
Glioblastoma is the most common and aggressive malignant tumor of the central nervous system. Despite the existing high unmet medical needs, the past few decades have seen no notable improvement in overall survival for glioblastoma patients. One active area of research to develop new therapeutic options for this disease is focusing on the CD95/Fas receptor and its ligand CD95L/FasL. It is now recognized that in addition to its role in programmed cell death, CD95/CD95L signaling is involved in a wide range of other apoptotic and non-apoptotic pathways directed toward T-effector cells and cells in the tumor microenvironment involved in tumor progression and invasiveness. Asunercept is a first-in-class recombinant glycosylated fusion protein, which has been designed to selectively bind to CD95L and therefore disrupt CD95/CD95L signaling. The current report provides a brief overview of the role of the CD95/CD95L signaling pathway in cancer pathogenesis and discusses how asunercept was designed to bind and neutralize CD95L and disrupt signaling thereby potentially improving outcomes in glioblastoma and other malignancies.
Insights
New glioblastoma treatments target the CD95/Fas receptor pathway. Asunercept, a novel fusion protein, neutralizes CD95 Ligand (CD95L) to disrupt signaling and potentially improve patient survival.
Area of Science:
- Neuro-oncology
- Immunology
- Molecular Biology
Background:
- Glioblastoma is an aggressive brain tumor with limited treatment options.
- The CD95/Fas receptor and its ligand (CD95L/FasL) pathway plays a role in cancer progression.
- CD95/CD95L signaling influences tumor microenvironment and immune response.
Purpose of the Study:
- To review the role of CD95/CD95L signaling in cancer.
- To introduce Asunercept as a therapeutic agent targeting CD95L.
- To discuss the potential of Asunercept in treating glioblastoma and other cancers.
Main Methods:
- Literature review on CD95/CD95L signaling in cancer pathogenesis.
- Description of Asunercept's design as a CD95L-binding fusion protein.
- Analysis of Asunercept's mechanism to disrupt CD95/CD95L signaling.
Main Results:
- CD95/CD95L signaling is implicated in tumor progression and invasiveness.
- Asunercept selectively binds and neutralizes CD95L.
- Disruption of CD95/CD95L signaling is a potential therapeutic strategy.
Conclusions:
- Asunercept is a promising therapeutic candidate for glioblastoma.
- Targeting CD95L with Asunercept may offer improved outcomes in malignancies.
- Further research is warranted to evaluate Asunercept's efficacy in clinical settings.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Related Concept Videos
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...